Warsaw, 24.05.2023r.
place and date

PRICE INQUIRY NO. SEMA/5/2023/API
being conducted as a market assessment study

Pertaining to the implementation of the project titled "Design and development of an innovative solution - a generic drug belonging to the class of GLP-1 receptor agonists in the treatment of type 2 diabetes", co-financed from the state budget funds in the framework of competitions conducted by the Medical Research Agency, Warszawskie Zakłady Farmaceutyczne Polfa S.A. you are kindly requested to submit a quotation for purchase and supply of the active substance Semaglutide ($C_{187}H_{291}N_{45}O_{59,}$ CAS 910463-68-2) described in detail in Section III.

I. NAME AND ADDRESS OF THE CUSTOMER

Warszawskie Zakłady Farmaceutyczne Polfa S.A.
ul. Karolkowa 22/24
01-207 Warszawa

II. CONTRACT AWARD PROCEDURE

1. This contract is not subject to the provisions of the Public Procurement Law of 11 September 2019 (consolidated text: Journal of Laws of 2019, item 2019).
2. The procedure is being conducted as an intentional and cost-efficient market assessment study while respecting the following rules:
   a) to achieve the best possible outcomes using the allocated resources;
   b) to choose the best possible means and methods to meet the pre-defined objectives;
   c) to ensure transparency, fair competition and equal treatment of contractors.

III. DESCRIPTION OF THE OBJECT OF THE PRICE INQUIRY

III.1. The object of this Price Inquiry is the purchase and supply of the active substance Semaglutide, ($C_{187}H_{291}N_{45}O_{59,}$ CAS 910463-68-2) obtained by chemical synthesis together with the associated standards of the active substance, standards of impurities specific to the active substance.

III.2. The object of contract will be acquired in two stages:

- **Stage I**: where the object of contract will be purchased from three different suppliers,
- **Stage II**: where the object of contract will be purchased from one supplier selected inStage I.

III.3. In Stage I, the object of contract will be purchased from the 3 suppliers who receive the highest score awarded under criterion A, whereas in Stage II, the object of contract will be purchased from only one supplier from among those selected in Stage I who will receive the highest total score summed from criteria A and B.

III.4. CPV CODE: 24950000-8 Specialist chemical products.

III.5. Scope of the Price Inquiry:

Stage I:

III.5.1. delivering 4 grams of Semaglutide per anhydrous substance, together with the certificate of analysis

III.5.2. delivering certified standard of the active substance in a quantity of not less than 20 mg and the associated declaration of recertification of the standard in the event of a shelf life of less than 1 year from the date of delivery

III.5.3. delivering certified impurity standards of the active substance included in the material specification, in a quantity not less than sufficient to enable analytical tests to be carried out in accordance with the method described by the supplier and the associated declaration of recertification of the standard in the event of a shelf life of less than 6 months from the date of delivery. (The final quantity will be confirmed at the order placement stage and will be estimated on the basis of the quotation presented for the standard weights that are available from the substance supplier). The Customer reserves the right to change the range of standards ordered, particularly in the event of overlapping impurity standards from suppliers. Manufacturer's declared price for the standards, included in Appendix 2 to this Price Inquiry.

III.5.4. ensuring that the developed active substance complies with the quality requirements, including but not limited to those specified in ICH Q6A, ICH Q11, monograph EP 2034 *Substances for pharmaceutical use*, monograph USP1503 *Quality attributes of synthetic peptide drug substances*.

Stage II:

III.5.5. delivering up to 600 grams of Semaglutide ($C_{187}H_{291}N_{45}O_{59}$, CAS 910463-68-2 as per anhydrous substance) of the material manufactured under GMP conditions

III.5.6. the material should be supplied in the quantity and in accordance with the schedule as in the table below:

Quantity [g/batches]	**Number of batches**	**Delivery date – not later than:**
up to 40	2	10.2023
up to 50	2	07.2024
up to 140	3	09.2025

III.5.7. the offered price includes all costs related to the delivery of the contract, including transport, insurance, etc.

III.5.8. the Customer reserves the right to change the quantity of the ordered material, the active substance semaglutide.

III.5.9. expiry date of the object of contract not shorter than 18 months from the declared expiry date

III.5.10. delivering the standard of the active substance and the standards of impurities: the Customer shall confirm the number of standards during project implementation once the knowledge of quality control of the drug formulation under development has been established.

III.6. Partial bids or variants will not be accepted.

IV. PRICE INQUIRY DELIVERY SITE AND DATE

IV.1. Deadline for delivery of the object of contract:

IV.1.1. **Stage I – the object of contract is planned to be delivered within 2 months of the order placement date.**
The tender evaluation in Stage I shall be decided not later than within 3 weeks of the bidding deadline.

IV.1.2. **Stage II – the object of contract is planned to be delivered within the time limits consistent with the schedule specified in the table in Section III.5.6 and not later than 2 months of the order placement date.**
The tender evaluation in Stage II shall be decided not later than within 18 weeks of the bidding deadline.

IV.2. Delivery location: CIP Warsaw.

V. REQUIREMENTS FOR CONTRACTORS

V.1. The procedure is open to any Contractors who meet all of the following requirements:

V.1.1. possession of knowledge and experience in the manufacture of active substances belonging to the class of synthetic peptides in a quality system compliant with GMP

V.1.2. possession of experience in preparing the registration dossier for the active substance belonging to the class of synthetic peptides, as confirmed by the number of registration submissions – at least two submissions are required.

V.1.3. providing the quality documentation with the open part of the ASMF/DMF on the day of submission of the quotation, and if full documentation is not available on the day of submission of the quotation, providing partial documentation to enable evaluation of the material quality.
If no full quality documentation is available, it is required to submit a declaration on the date of its submission and to submit partial documentation necessary for the assessment of the material, not later than by the closing date for the submission of quotations. Such partial documentation shall include, among others, material specification, description of the methods used for substance control, detailed description of impurities, source of their origin, stress tests, minimum 6-month stability tests from accelerated conditions and demonstration of substance sameness with respect to the original drug.

V.1.4. provide, at the stage of submitting the quotation, data confirming the performance of an assessment of the sameness of the offered substance with respect to the active substance of the reference product in accordance with the current FDA recommendation *ANDAs for Certain Highly Purified Synthetic Peptides_Drug Products That Refer to Listed Drugs of rDNA Origin* by presenting the results of tests of the active substance, including:
a) comparison of the primary structure and peptide sequence,

b) comparison of the secondary structure,
c) comparison of the higher order structure,
d) evidencing a similar profile and level of impurities (impurities not higher than in the original drug),
e) demonstrating equivalent biological activity, preferably in vitro test
f) other tests confirming the spatial structure,
g) other tests demonstrating the sameness of the active substance with respect to the reference product.

V.1.5. 4 grams of Semaglutide (Stage I) are to come from one certified batch which fully represents the material from the final process (synthesis process and requirements) but can be manufactured under non-GMP conditions. The certificate should be attached to the quotation together with the declaration that the material originates from the final synthesis process.

Assessment procedure:
The Customer will consider Contractor as meeting this condition if Contractor submits a declaration of compliance with the conditions for participation in the procedure (Appendix 3 to the Price Inquiry).

The Customer reserves the right to verify the fulfilment of the conditions at the Bidder's site or to call for relevant documentation to be submitted.

V.2. Quotations submitted by Contractors who demonstrate that they meet the specified requirements will be taken forward to the quotation examination and assessment stage. The compliance with the above requirements will be assessed based on a "meet – does not meet" basis. Quotations submitted by Contractors who fail to meet any of the above requirements will be rejected.

V.3. Entities for which the following circumstances occur are excluded from the tender:
a) as described in Article 7(1) of the Act of 13 April 2022 on Special Measures to Counteract Support for the Aggression against Ukraine and to Protect National Security;
b) as described in Article 5k of the Council Regulation (EU) No 833/2014 of 31 July 2014 concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine

Method of verification of grounds/lack of grounds for exclusion:
The verification shall take place on the basis of the Bidder's declaration.

VI. PLACE AND DEADLINE FOR SUBMISSION OF QUOTATIONS

VI.1. The final deadline for submitting quotations is 31.05.2023r.
– quotations can be sent in electronic format (in the form of a scan of the signed document) to the following address: barbara.wendolowska@polpharma.com

VI.2. A quotation will be considered to have been properly submitted if a complete quotation is delivered to the above email address within the time limit stipulated in this section.

VI.3. No quotations submitted past the submission deadline will be considered.

VII. CONTRACT AWARD CRITERIA

VII.1 The following criteria will be used by the Customer for the assessment of quotations:

VII.1.1 Stage I Criterion A (selection of three suppliers)

a) total net price of Semaglutide per gram of substance per anhydrous material – up to 25 points,
b) number of orthogonal analytical techniques used to confirm the sameness of the active substance with respect to the reference product, the techniques cover the scope recommended by the FDA guideline (section V.1.4 subsections a to e) – up to 40 points,
c) number of batches of the reference product used in the assessment of the sameness of the active substance with respect to the reference product – up to 15 points,
d) quality documentation compliant with EU requirements (ASMF doc) and US requirements (DMF doc) – up to 20 points

VII.1.2 Stage II Criterion B, purchase of the substance from the selected supplier

e) total net price of Semaglutide per gram of substance per anhydrous material – up to 50 points,
f) quality of the material tested in Stage I by the Customer coincides with the quality declared by the supplier – up to 50 points.

VII.2 The scoring of the quotation for Stage I will be calculated according to the following formula:

$$\boldsymbol{O_P = P_{C1} + P_M + P_D + P_K}$$

where:

O_P - score of the quotation

P_{C1} - score for the criterion: “total net price of Semaglutide per gram of substance per anhydrous material”

P_M - score for the criterion: “number of orthogonal analytical techniques used to confirm the sameness of the active substance with respect to the reference product, the techniques cover the scope recommended by the FDA guideline”

P_D - score for the criterion: “number of batches of the reference product used in the assessment of the sameness of the active substance with respect to the reference product”

P_K - score for the criterion: “quality documentation compliant with EU requirements (ASMF doc) and US requirements (DMF doc)”

VII.3 Score (P_C) for the criterion: "total net price of Semaglutide per gram of substance per anhydrous material" will be calculated according to the following formula:

$$P_{C1} = \left[1 - \frac{(C_x - C_{min})}{(C_{max} - C_{min})}\right] * 25\ points$$

where:

- P_{C1} - score for the criterion: "total net price of Semaglutide per gram of substance per anhydrous material"
- C_{min} - the lowest total net price based on non-rejected quotations
- C_x - total net price of the quotation under evaluation
- C_{max} - the highest total net price based on non-rejected quotations

Quotations with the price given in a currency other than PLN will be converted to PLN at the average exchange rate of the National Bank of Poland as at the final date for the submission of quotations.

VII.4 Score (P_M) for the criterion: "number of orthogonal analytical techniques used to confirm the sameness of the active substance with respect to the reference product, the techniques cover the scope recommended by the FDA guideline (section V.1.4 subsections a to e) will be calculated as follows:

$$P_M = \frac{(M_x - M_{\min})}{(M_{max} - M_{min})} * 40\ points$$

where:

- P_M - score for the criterion: "number of orthogonal analytical techniques used to confirm the sameness of the active substance with respect to the reference product, the techniques cover the scope recommended by the FDA guideline (section V.1.4 subsections a to e)
- M_{min} - based on non-rejected quotations, the lowest total number of techniques used
- M_x - total number of techniques used for the examined quotation
- M_{max} - based on non-rejected quotations, the highest total number of techniques used

VII.5 Score (P_T) for the criterion: "number of batches of the reference product used in the assessment of the sameness of the active substance with respect to the reference product" will be calculated as follows:

$$P_T = \frac{(P_x - P_{min})}{(P_{max} - P_{min})} * 15\ points$$

where:

- P_T - score for the criterion: "number of batches of the reference product used in the assessment of the sameness of the active substance with respect to the reference product"

P_{min} - based on non-rejected quotations, the lowest total number of reference product batches
P_x - total number of reference product batches in the examined quotation
P_{max} - based on non-rejected quotations, the highest total number of reference product batches

VII.6 Score (P_T) for the criterion: "quality documentation compliant with EU requirements (ASMF doc) and US requirements (DMF doc)" will be calculated as follows:

- For enclosing EU compliant quality documentation (APMF doc) – 10 points
- For enclosing US compliant quality documentation (DMF doc) – 10 points

VII.7 The scoring of the quotation for Stage II will be calculated according to the following formula:

$$\boldsymbol{O_{P2} = P_{C2} + P_Q + O_{P1}}$$

where:

O_{P2} - the quotation scoring
P_{C2} - score for the criterion: "total net price of Semaglutide per gram of substance per anhydrous material"
P_Q - score for the criterion: "quality of the material tested in Stage I by the Customer coincides with the quality declared by the supplier"
O_{P1} - score for Stage I

VII.8 Score (P_C) for the criterion: "total net price of Semaglutide per gram of substance per anhydrous material" for Stage II will be calculated according to the following formula:

$$P_{C2} = \left[1 - \frac{(C_x - C_{min})}{(C_{max} - C_{min})}\right] * 50\ points$$

where:

P_{C2} - score for the criterion: "total net price of Semaglutide per gram of substance per anhydrous material"
C_{min} - the lowest total net price based on non-rejected quotations
C_x - total net price of the quotation under evaluation
C_{max} - the highest total net price based on non-rejected quotations

Quotations with the price given in a currency other than PLN will be converted to PLN at the average exchange rate of the National Bank of Poland as at the final date for the submission of quotations.

VII.9 Score (P_M) for the criterion: "quality of the material tested in Stage I by the Customer coincides with the quality declared by the supplier" will be calculated as follows:

- the Customer received the result of the analyses for selected quantitative parameters as regards the specification received from the supplier in Stage I – 50 points
- the Customer received the results of the analyses for selected quantitative parameters outside the scope of the specification declared by the supplier – 0 points.

VII.10 A maximum the Bidder may obtain:

- a total of up to 100 points in Stage I,
- a total of up to 200 points in Stage II,

Calculations will be made to two decimal places.

VII.10.1 In Stage I, the object of contract will be purchased from 3 suppliers who will receive the highest score awarded under criterion A.

VII.10.2 In Stage II, the object of contract will be purchased from only one supplier from among those selected in Stage I who will receive the highest total score summed from criteria A and B.

VIII. PREPARATION OF QUOTATIONS

VIII.1. The Bidder should draw up one quotation using the quotation form attached as Appendix 1 hereto.

VIII.2. Quotations may be modified or withdrawn prior to the end of the time limit for the submission of quotations.

VIII.3. Bidders are required to carefully read the information contained in the Price Inquiry.

VIII.4. For any matters related to this Price Inquiry, please contact the Customer, email: barbara.wendolowska@polpharma.com

IX. ADDITIONAL INFORMATION

IX.1. Any costs and expenses incurred in connection with the preparation and submission of quotations are to be paid by the respective Bidders.

IX.2. Until the end of the time limit for the submission of quotations, the Customer reserves the right to amend or add new information to this Price Inquiry.

X. LIST OF APPENDICES

The following appendices are attached to this Price Inquiry:

Appendix number	Appendix title
Appendix 1	Quotation form
Appendix 2	Information Quotation Form Standards
Appendix 3	Model statement on fulfilment of the conditions set out in the Price Inquiry

Appendix 1 to the Price Inquiry No. ***SEMA/5/2023/API***

QUOTATION FORM

Bidder:

Name / Company	
Registered office/place of residence/address of the principal place of business	
Email address for the Customer to send correspondence related to the Price Inquiry	
NIP [Taxpayer ID Number]	
REGON [Statistical ID Number]	
Phone number	
Contact person for the Customer	

We offer to perform the object of contract as regards t*he purchase and supply of the active substance Semaglutide (INN) obtained by chemical synthesis together with the associated standards of the active substance, standards of impurities specific to the active substance* in accordance with the requirements of the Price Inquiry, for the following **price**

in Stage 1: net amount: PLN …… per gram of substance per anhydrous material in Stage I

VAT rate: ……%, VAT amount: PLN ……

gross amount: PLN ……

in Stage 2: net amount: PLN …… per gram of substance per anhydrous material in Stage II

VAT rate: ……%, VAT amount: PLN ……

gross amount: PLN ……

Contract delivery date:
…….. months from the date of order placement in Stage I
…….. months from the date of order placement in Stage II

We also declare as follows:

a. We have read the Price Inquiry and appendices thereto and we raise no objections, and we have obtained the information necessary to prepare our quotation.

b. Our quotation price includes a lump sum remuneration that covers all the obligations of the future Contractor as necessary to deliver the contract referred to hereunder.

c. by submitting this quotation we represent that we meet the conditions for participation set out in Section V of this Price Inquiry.

d. by submitting this quotation we represent that there are no circumstances in relation to us:

- as described in Article 7(1) of the Act of 13 April 2022 on Special Measures to Counteract Support for the Aggression against Ukraine and to Protect National Security;
- as described in Article 5k of the Council Regulation (EU) No 833/2014 of 31 July 2014 concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine.

…… ……

(place and date) (signature)

Appendix 2 to the Price Inquiry No. ***SEMA/5/2023/API***

INFORMATION QUOTATION FORM STANDARDS

Bidder:

Name / Company	
Registered office/place of residence/address of the principal place of business	
Email address for the Customer to send correspondence related to the Price Inquiry	
NIP [Taxpayer ID Number]	
REGON [Statistical ID Number]	
Phone number	
Contact person for the Customer	

We offer to provide the active substance standard, active substance specific impurity standards at a price in accordance with the price information shown in the table below (the price specified for the different weight available to be ordered):

Active substance standard

	Active substance standard
Quantity required for a single analysis (g)	**……. (g)**
minimum packaging (g)	**…….. (g)**
Price for minimum packaging (PLN)	**PLN …… net, PLN …….. gross**
If the Bidder has different packaging capacities, the Bidder shall fill in **Packaging capacities (g), net price (PLN), gross price (PLN)**	 **…… (g), PLN …… net, PLN …….. gross** **…… (g), PLN …… net, PLN …….. gross** **…… (g), PLN …… net, PLN …….. gross**

Impurity standard no. 1*

Impurity standard	
Name used by the supplier	
Chemical name	
Chemical formula	
Quantity required for a single analysis (g)	**……. (g)**
minimum packaging (g)	**…….. (g)**
Price for minimum packaging (PLN)	**PLN …… net, PLN …….. gross**
If the Bidder has different packaging capacities, the Bidder shall fill in **Packaging capacities (g), net price (PLN), gross price (PLN)**	**…… (g), PLN …… net, PLN …….. gross** **…… (g), PLN …… net, PLN …….. gross** **…… (g), PLN …… net, PLN …….. gross**

***With more impurities, duplicate the Impurity Standard Table with subsequent numbers as appropriate.**

…… ……

(place and date) (signature)

*Appendix 3 to the Price Inquiry No **SEMA/5/2023/API***

STATEMENT ON FULFILMENT OF THE CONDITIONS SET OUT IN THE PRICE INQUIRY

... ... *(name of the Bidder)* declares that it meets the conditions set out in the Price Inquiry within the following scope:

1. possession of knowledge and experience in the manufacture of active substances belonging to the class of synthetic peptides in a quality system compliant with GMP

2. possession of experience in preparing the registration dossier for the active substance belonging to the class of synthetic peptides, as confirmed by the number of registration submissions – at least two submissions are required.

3. providing the quality documentation with the open part of the ASMF/DMF on the day of submission of the quotation, and if full documentation is not available on the day of submission of the quotation, providing partial documentation to enable evaluation of the material quality.
   If no full quality documentation is available, it is required to submit a declaration on the date of its submission and to submit the partial documentation necessary for the assessment of the material, not later than by the day when the quotations are submitted. Such partial documentation shall include, among others, material specification, description of the methods used for substance control, detailed description of impurities, source of their origin, stress tests, minimum 6-month stability tests from accelerated conditions and demonstration of substance sameness with respect to the original drug.

4. provide, at the stage of submitting the quotation, data confirming the performance of an assessment of the sameness of the offered substance with respect to the active substance of the reference product in accordance with the current FDA recommendation *ANDAs for Certain Highly Purified Synthetic Peptides Drug Products That Refer to Listed Drugs of rDNA Origin* by presenting the results of tests of the active substance, including:
   a) comparison of the primary structure and peptide sequence,
   b) comparison of the secondary structure,
   c) comparison of the higher order structure,
   d) evidencing a similar profile and level of impurities (impurities not higher than in the original drug),
   e) demonstrating equivalent biological activity, preferably in vitro test
   f) other tests confirming the spatial structure,
   g) other tests demonstrating the sameness of the active substance with respect to the reference product.

5. 4 grams of Semaglutide (Stage I) are to come from one certified batch which fully represents the material from the final process (synthesis process and requirements), but can be manufactured in non-GMP conditions. The certificate should be attached to the quotation together with the declaration that the material originates from the final synthesis process.

…… ……

(place and date) (signature)